Document is current
Any future updates will be listed below
-
Authors
Amedick, Greta
Krylova, Marina
Mayer, Kathrin
Izyurov, Igor
Herrmann, Luisa
Martens, Louise
Kasties, Vanessa
Heller, Johanna
Li, Meng
van der Meer, Johan https://orcid.org/0000-0003-2737-2691
Croy, Ilona
Engert, Veronika
Walter, Martin
Colic, Lejla https://orcid.org/0000-0002-8809-4034
-
Funding
Funding for this research was provided by:
Interdisciplinary Center of Clinical Research of the Medical Faculty Jena
German Research Foundation Grants (DFG) No. SFB779/A06, and EU-ERA-Net: Neuromarket (MW).
Universitätsklinikum Jena
- License Information
-
More Information
Article History
Received: 6 June 2023
Accepted: 12 March 2024
First Online: 25 March 2024
Competing interests
: MW is a member of the following advisory boards and gave presentations to the following companies: Bayer AG, Germany; Boehringer Ingelheim, Germany; and Biologische Heilmittel Heel GmbH, Germany. MW has further conducted studies with institutional research support from HEEL and Janssen Pharmaceutical Research for a clinical trial (IIT) on ketamine in patients with MDD, unrelated to this investigation. MW did not receive any financial compensation from the companies mentioned above. All other authors declare no competing interests.
